Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of the study is to examine the effect of testosterone treatment on insulin in men with the metabolic syndrome with testosterone levels at or below the lower end of the normal range.
| Condition | Intervention |
|---|---|
|
Metabolic Syndrome |
Drug: Zoladex Drug: AndroGel Drug: Arimidex |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome |
- Fasting Insulin
- Fasting Glucose
- Testosterone
- Estradiol
- cholesterol, HDL, LDL, triglycerides
- SHBG, LH, FSH, PRL, TSH
- cytokines
- percent body fat
- Resting Metabolic Rate
- Aerobic capacity
| Estimated Enrollment: | 72 |
| Study Start Date: | September 2006 |
| Estimated Study Completion Date: | September 2010 |
| Estimated Primary Completion Date: | September 2010 (Final data collection date for primary outcome measure) |
The metabolic syndrome is a medical condition defined by high cholesterol levels, high blood pressure, increased abdominal obesity (gain in fat around the region of the stomach), and insulin resistance. Insulin is the hormone that your body produces to decrease the levels of sugar in your blood. A person that is insulin resistant needs more insulin to decrease blood sugar levels than a normal person does. Insulin resistance can lead to type 2 diabetes, which is one of the most common illnesses in the United States.
There is evidence pointing to a relationship between insulin and testosterone in men (testosterone is the male sex hormone that is produced in the testes). As men get older their testosterone levels decrease while their weight and insulin resistance tends to increase. The purpose of this research study is to learn more about the details of the relationship between insulin and testosterone. A clearer understanding of this relationship can have an important impact on public health due to the high rate of health problems associated with diabetes, obesity, and heart disease.
We are looking for men between the ages of 50-75 with the metabolic syndrome to participate in this research study. Participation in this study involves taking medication and/or placebo (a placebo looks exactly like the study medication but contains no active drug), blood tests, muscle biopsies, and imaging scans. This study involves outpatient visits. Subjects are paid up to $500 for completing the study.
Eligibility| Ages Eligible for Study: | 50 Years to 75 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Stable weight for previous three months (no weight change greater than or equal to +/-10 lbs)
Exclusion Criteria:
- No new diagnosis of type 2 diabetes or on oral hypoglycemic agents
- No history of testicular disorders
- No history of bleeding disorders (i.e. Pulmonary Embolism, Deep Vein Thrombosis, stroke, hypercoagulable syndrome)
- No history of prostate cancer
- No previous diagnosis of osteoporosis
- No history of sleep apnea (subjects will also be excluded if at their baseline assessment they admit to heavy snoring, restless sleep, and/or excessive daytime somnolence)
- No symptoms of urinary outflow obstruction or medications for prostate disease
- No illicit drug use or heavy alcohol use (>4 drinks/day)
Contacts and Locations| Contact: Lindsay A Edwards | 617-726-8436 | ledwards@partners.org |
| United States, Massachusetts | |
| Massachusetts General Hospital | Recruiting |
| Boston, Massachusetts, United States, 02114 | |
| Principal Investigator: Frances J Hayes, MD | |
| Principal Investigator: | Frances J Hayes, MD | Massachusetts General Hospital |
More Information
Additional Information:
Publications:
| ClinicalTrials.gov Identifier: | NCT00438321 History of Changes |
| Other Study ID Numbers: | 2003-P-001526 |
| Study First Received: | February 20, 2007 |
| Last Updated: | May 3, 2010 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Massachusetts General Hospital:
|
Overweight obesity testosterone |
diabetes metabolic syndrome aging |
Additional relevant MeSH terms:
|
Metabolic Syndrome X Insulin Resistance Glucose Metabolism Disorders Metabolic Diseases Hyperinsulinism Testosterone Testosterone enanthate Testosterone undecanoate Testosterone 17 beta-cypionate Methyltestosterone Goserelin Anastrozole |
Androgens Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents, Hormonal Antineoplastic Agents Therapeutic Uses Anabolic Agents Aromatase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |
ClinicalTrials.gov processed this record on June 17, 2013